Botulinum toxin injection therapy in the management of lower urinary tract dysfunction

International Journal of Clinical Practice

Volumn 60, Issue SUPPL. 151, 2006, Pages 1-7

  Patel, A K ^a   Chapple, C R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Botox ; Botulinum toxin; Detrusor sphincter dyssynergia; Lower urinary tract; Neurogenic; Neurogenic idiopathic detrusor overactivity; Overactive bladder; Prostate; Sensory bladder disorders; Urgency; Urothelium

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO; MUSCLE RELAXANT AGENT;

ANTINOCICEPTION; ARM WEAKNESS; AUTONOMIC DYSREFLEXIA; BLADDER COMPLIANCE; BLADDER NECK STENOSIS; CLINICAL RESEARCH; CLINICAL TRIAL; CYSTALGIA; CYSTOSCOPE; DETRUSOR DYSSYNERGIA; DISEASE EXACERBATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INJECTION VOLUME; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; INJECTION SITE; INJECTION SITE PAIN; MICTURITION DISORDER; NEUROGENIC BLADDER; NONHUMAN; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; OUTPATIENT CARE; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; RETREATMENT; SAMPLE SIZE; STRESS INCONTINENCE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; URINE RETENTION; URINE VOLUME; UROGENITAL TRACT DISEASE; BLADDER DISEASE; DRUG ADMINISTRATION; REVIEW;

BOTULINUM TOXIN TYPE A; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEUROMUSCULAR AGENTS; URINARY BLADDER DISEASES; URINATION DISORDERS;

EID: 33751329323     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01181.x     Document Type: Editorial

References (59)

1. Smith CP, Somogyi GT, Boone TB. Botulinum toxin in urology: Evaluation using an evidence-based approach. Nat Clin Pract Urol 2004; 1: 31-7.
2. Andersson K-E. Treatment-resistant detrusor overactivity-underlying pharmacology and potential mechanism. Int J Clin Pract 2006; 60 (Suppl. 151): 8-16.
3. Castro-Diaz D, Taracena Lafuente JM. Detrusor-sphincter dyssynergia. Int J Clin Pract 2006; 60 (Suppl. 151): 17-21.
4. Cruz F, Silva C. Refractory neurogenic detrusor overactivity. Int J Clin Pract 2006; 60 (Suppl. 151): 22-26.
5. Patel AK, Patterson JM, Chapple CR. The emerging role of intravesicle botulinum toxin therapy in idiopathic detrusor overactivity. Int J Clin Pract 2006; 60 (Suppl. 151): 27-32.
6. Thomas CA, Guercini F, Chuang Y-C, Chancellor MB. Botulinum-A toxin: An exciting new treatment option for prostatic disease. Int J Clin Pract 2006; 60 (Suppl. 151): 33-37.
7. Nordling J. Sensory bladder disorders. Int J Clin Pract 2006; 60 (Suppl. 151): 38-42.
8. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: Current state of the art. Eur Urol 2003; 44: 165-74.
9. Harper M, Fowler CJ, Dasgupta P. Botulinum toxin and its applications in the lower urinary tract. BJU Int 2004; 93: 702-6.
10. Maria G, Cadeddu F, Brisinda D, Brandara F, Brisinda G. Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin. Curr Med Chem 2005; 12: 247-65.
11. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47: 653-9.
12. Silberstein SD, Aoki KR. Botulinum toxin type A: Myths, facts, and current research. Headache 2003; 43: S1-1.
13. Reitz A, Schurch B. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 2004; 171: 804-5.
14. Truzzi JC, Bruschini H, Simonetti R, Miguel S. What is the best dose for intravesical botulinum-A toxin injection in overactive bladder treatment? A prospective randomised preliminary study. Joint meeting of the International Continence Society (ICS) and the International Uro-Gynaecological Association (IUGA) 2004; 520 (Abstract).
15. Gousse A, Tunuguntla HSGR, Rodriguez D, Velazquez D. Dose-finding prospective randomized study to evaluate the efficacy and safety of botulinum-A toxin for refractory idiopathic overactive bladder. Int Continence Soc Ann Meet 2005; 254 (Abstract).
16. Radziszewski P, Borkowski A. Botulinum toxin type A intravesical injections for intractable bladder overactivity. Eur Urol Suppl 2002; 1: 134. (Abstract).
17. Del Popolo G, Li Marzi V, Panariello G, Lombardi G. English botulinum toxin-A in the treatment of neurogenic detrusor overactivity. Int Continence Soc Ann Meet 2003; 96 (Abstract).
18. Schurch B, Stohrer M, Kramer G, Grosse J, Schmid D, Hauri D. Botulinum toxin-A to treat detrusor hyperreflexia in spinal cord injured patients. Neurourol Urodyn 2001; 20: 521-2 (Abstract).
19. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004; 63: 868-72.
20. Karsenty G, Boy S, Reitz A et.al. Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI) -a prospective randomized study to compare 30 vs. 10 injection sites. Int Continence Soc Ann Meet 2005; 93 (Abstract).
21. Reitz A, Stohrer M, Kramer G et.al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510-5.
22. Harper M, Popat RB, Dasgupta R, Fowler CJ, Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003; 92: 325-6.
23. Zermann DH, Ishigooka M, Schmidt RA. Trigonum and bladder base injection of botulinum toxin A (BoNT) in patients with severe urgency-frequency syndrome refractory to conservative medical treatment and electrical stimulation. Neurourol Urodyn 2001;20: 412-3 (Abstract).
24. Kennelly MJ, Kang J. Botulinum-A toxin injections as a treatment for refractory detrusor hyperreflexia. Top Spinal Cond Inj Rehabil 2003; 8: 46-53.
25. Karsenty G, Lindemann G, Reitz A, Roy S, Boy S, Schurch B. The effect of repeated injections of botulinum toxin type A on the efficacy of the treatment of neurogenic overactive bladder and the urinary bladder. Int Continence Soc Ann Meet 2005; 242: Abstract.
26. Rackley R, Abdelmalak J. Urologic applications of botulinum toxin therapy for voiding dysfunction. Curr Urol Rep 2004; 5: 381-8.
27. Pistolesi D, Selli C, Rossi B, Stampacchia G. Botulinum toxin type B for type A resistant bladder spasticity. J Urol 2004; 171: 802-3.
28. Smith CP, Chancellor MB Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004; 171 (6 Pt 1): 2128-37 (Review).
29. Dykstra DD, Sidi A. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study. Arch Phys Med Rehabil 1990; 71: 24-6.
30. Fowler CJ, Betts CD, Christmas TJ, Swash M, Fowler CG. Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol 1992; 70: 387-9.
31. Petit H, Wiart E, Gaujard E et.al. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 1998; 36: 91-4.
32. Del Popolo G. Botulinum-A toxin in the treatment of detrusor hyperreflexia. Neurourol Urodyn 2001; 20: 522.
33. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002; 40: 599-600.
34. Montecucco C, Molgo J. Botulinal neurotoxins: Revival of an old killer. Curr Opin Pharmacol 2005; 5: 274-9.
35. Kumar V, Chapple C, Chess-Williams R. ATP release from normal human urinary bladder and porcine bladder. Eur Urol Suppl 2004; 3: 76 (Abstract 294).
36. Sui GP, Wu C, Fry CH. Electrical characteristics of suburothelial cells isolated from the human bladder. J Urol 2004; 171: 938-43.
37. Kumar V, Chapple C, Chess-Williams R. Distribution of purinergic receptors in urinary bladder of porcine and normal human urinary bladder. Eur Urol Suppl 2004; 3: 76. (Abstract 296).
38. Fowler CJ. Bladder afferents and their role in the overactive bladder. Urology 2002; 59: 37-42.
39. Kumar V, Chapple C, Rosario DJ, Chess-Williams R. Purinergic activity in sensory disorders of the bladder. Eur Urol Suppl 2004; 3: 76. (Abstract 295).
40. Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004; 45: 987-93.
41. Atiemo H, Wynes J, Chuo J, Nipkow L, Sklar GN, Chai TC. Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology 2005; 65: 622-6.
42. Apostolidis A, Popat R, Yiangou Y et.al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-83.
43. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 2004; 64: 871-5.
44. Vemulakonda VM, Somogyi GT, Kiss S, Salas NA, Boone TB, Smith CP. Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol 2005; 173: 621-4.
45. Cruz F, Silva C. Botulinum toxin in the management of lower urinary tract dysfunction: Contemporary update. Curr Opin Urol 2004; 14: 329-34.
46. Smith CP, Boone TB, de Groat WC, Chancellor MB, Somogyi GT. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull 2003; 61: 165-71.
47. Smith CP, Vemulakonda VM, Kiss S, Boone TB, Somogyi GT. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A. Neurochem Int 2005; 47: 291-7.
48. Smith CP, Franks ME, McNeil BK et.al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003; 169: 1896-900.
49. Sahai A, Khan M, Fowler CJ, Dasgupta P. Botulinum toxin for the treatment of lower urinary tract symptoms: A review. Neurourol Urodyn 2005; 24: 2-12.
50. Giannantoni A, Nardicchi V, Di Stasi S et.al. Botulinum A toxin intravesical injections reduce nerve growth factor bladder tissue content in patients affected by neurogenic detrusor overactivity. Int Continence Soc Ann Meet 2005; 221 (Abstract).
51. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139: 919-22.
52. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: A prospective study in 24 spinal cord injury patients. J Urol 1996; 155: 1023-9.
53. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342: 665.
54. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692-7.
55. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox induced prostatic involution. Prostate 1998; 37: 44-50.
56. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology 2003; 62: 259-65.
57. Aoki KR. Pharmacology and immunology of botulinum toxin type A. serotypes. Clin Dermatol 2003; 21: 476-80.
58. Thomson AJ, Jarvis SK, Lenart M, Abbott JA, Vancaillie TG. The use of botulinum toxin type A (BOTOX) as treatment for intractable chronic pelvic pain associated with spasm of the levator and muscles. BJOG 2005; 112: 247-9.
59. Chapple C, Patel A. Botulinum toxin-new mechanisms, new therapeutic directions? Eur Urol 2006; 49: 606-8.